SMU chemistry professor John Buynak and his team have received a $3.5 million, 5-year grant from the National Institutes of Health to design and synthesize new antibiotics to fight some of the deadliest and most clinically challenging infections of the 21st century – drug resistant strains of bacteria that cause tuberculosis and leprosy.
Researchers at Sylvester Comprehensive Cancer Center found that robot-assisted surgeries and new patient-care protocols are enabling lung cancer surgery patients to go home earlier, with less pain and almost always without a need for potentially addictive opioids.
Texas Tech researchers are taking a closer look at drug-resistant organisms and searching for new ways to attack them.
Researchers have invented a nano-thin superbug-slaying material that could one day be integrated into wound dressings and implants to prevent or heal bacterial infections.
Researchers have received a U.S. patent for a novel method to identify therapeutic agents to treat addiction. The invention, related to the fields of pharmacology, medicine, neurology and psychiatry, targets the protein MBLAC1, which the Blakely lab identified as the mammalian form of a gene the group first identified in worms as a modifier of signaling by the neurotransmitter dopamine.
Research from Michigan State University has shown that more than 100 strains of Campylobacter jejuni, a leading cause of foodborne illness, circulating in Michigan are resistant to at least one antibiotic.
Bees could become biomonitors, checking their neighbourhoods to determine how far antimicrobial resistance (AMR) has spread, according to research by Macquarie University scientists.
Breast cancers with mutations in the HER2 gene are initially sensitive to HER2 inhibitors like neratinib. However, most tumors eventually become resistant.
A new powerful antibiotic, isolated from bacteria that could not be studied before, seems capable to combat harmful bacteria and even multi-resistant ‘superbugs’.
Scientists at St. Jude Research Hospital unravel the mechanisms behind a key culprit in chemotherapy resistance.
Current methods can vastly overestimate the rates that malaria parasites are multiplying in an infected person’s blood, which has important implications for determining how harmful they could be to a host, according to a new report.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Bacteria draw from an arsenal of weapons to combat the drugs intended to kill them. Among the most prevalent of these weapons are ribosome-modifying enzymes. These enzymes are growing increasingly common, appearing worldwide in clinical samples in a range of drug-resistant bacteria.
“Back-to-school” season means earaches. Today, a team reports a single-use nanoscale system unlikely to generate resistance. It can kill an ear-infection-causing bacterium in animals with a compound like bleach, and it could someday be used in a gel. They will present their results at ACS Fall 2023.
Each year, over 670,000 people in Europe fall ill because of antibiotic-resistant pathogens, and 33,000 die from the infections.
The National Cancer Institute (NCI) has awarded a 5-year, $2.7 million grant to researchers at Sanford Burnham Prebys to investigate and elucidate the underlying cellular mechanisms that drive the most common form of breast cancer.
Researchers have discovered a new way to attack fungal infections. The key is to block fungi from being able to make fatty acids, the major component of fats.
Researchers in UNC School of Medicine’s Department of Otolaryngology/Head and Neck Surgery and collaborators at Yale Cancer Center and ECOG-ACRIN Cancer Research Group have identified two subtypes of human papillomavirus positive head and neck cancers, giving them a better glimpse into why some patients respond better to treatment than others.
A first-of-its kind drug for prostate cancer, an ancient retrovirus that may drive aggressive brain cancer, disparities in endometrial cancer rates among Black women, a new trial seeking answers for higher rates of aggressive prostate and breast cancer in Black men and women, and more are in this month’s tip sheet from Sylvester Comprehensive Cancer Center.
The Association for Diagnostics and Laboratory Medicine (ADLM), formerly AACC, welcomed thousands of laboratory experts to the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo from July 23-27. At this year’s special meeting celebrating ADLM’s 75th anniversary, the organization officially rolled out a new name that reflects the association’s role as advocate and champion for a larger community specializing in diagnostics and laboratory medicine, as well as its global reach.
The discovery of antibiotics in 1928 was a major turning point in the history of medicine. For the first time since the dawn of human civilization, doctors had gained access to an extremely powerful and effective tool to fight against a wide variety of bacterial infections.
Penicillin allergy affects more than 25 million people in the United States (up to 1 in 10 Americans) and has been shown to lead to particularly poor health outcomes in pregnant women and surgical patients. It is also a public health threat, leading to antibiotic resistance and infections in hospitalized patients that can be life threatening.
A research study provides a transformational new insight into how antimicrobial resistance (AMR) emerges in patients with bacterial infections. The findings could help develop more effective interventions to prevent AMR infections developing in vulnerable patients.
Prostate cancer is resistant to one of the most powerful chemotherapy medications — cisplatin. Now, researchers in ACS Central Science have developed the first therapy of its kind that disrupts prostate cancer cells’ metabolism and releases cisplatin into the weakened cells, causing them to die.
Though antibiotics can treat leprosy, researchers are concerned about the increase in drug-resistant strains. Now, a team reporting in ACS Central Science has begun to understand the role certain immune receptors play in leprosy, which could lead to new types of treatments for this disease.
Scientists at McMaster University and India’s University of Delhi have discovered and isolated the first live culture of the drug-resistant pathogen Candida auris from an animal, specifically from the ear canals of stray dogs.
A team of scientists from around the globe, including those from Trinity College Dublin, has gained high-res structural insights into a key bacterial enzyme, which may help chemists design new drugs to inhibit it and thus suppress disease-causing bacteria.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for June 2023.
Researchers led by Lund University in Sweden have assisted microbiologists in Ukraine in investigating bacterial resistance among the war-wounded patients treated in hospitals.
Graham Hatfull has pioneered the use of bacteriophages, or just “phages,” to combat antibiotic resistant infections. He was honored with the Gardner Middlebrook Lifetime Achievement award for his research.
Therapy of the dangerous infectious disease of tuberculosis faces the challenge of pathogens frequently being resistant to several common antibiotics. Researchers of Karlsruhe Institute of Technology (KIT) have now developed nanoparticles to deliver new antibiotics directly to the lungs in future. Surfactants ensure that the highly fat-soluble antibiotics disperse very finely in water and can be inhaled. First tests at the Research Center Borstel, Leibniz Lung Center, reveal a high effectiveness and good compatibility of the nanocarriers of antibiotics. The researchers report in ACS Nano. (DOI: 10.1021/acsnano.3c01664)
For many patients with hypertension—an elevated blood pressure that can lead to stroke or heart attack—medication keeps the condition at bay. But what happens when medication that physicians usually prescribe doesn’t work? Known as apparent resistant hypertension (aRH), this form of high blood pressure requires more medication and medical management.
A genetic marker discovered by UT Southwestern Medical Center researchers could help physicians predict which patients with hepatocellular carcinoma are most likely to develop resistance to the drug lenvatinib. The finding, published in the journal Gastroenterology, may lead to alternative treatments for the most common form of liver cancer.
The drugs used to treat and prevent malaria in Mozambique are still effective, according to a genomic analysis of drug resistance markers in P. falciparum, carried out by the Barcelona Institute for Global Health (ISGlobal) and the Manhiça Health Research Center (CISM).
New McMaster research has found that a disease-causing fungus — collected from one of the most remote regions in the world — is resistant to a common antifungal medicine used to treat infections.
Researchers at the University of Birmingham have demonstrated that silver retains antimicrobial activity for longer when it is impregnated into ‘bioactive glass’, and shown for the first time how this promising combination delivers more long-lasting antimicrobial wound protection than conventional alternatives.
UT Southwestern Medical Center and its William P. Clements Jr. University Hospital have been named an Antimicrobial Stewardship Center of Excellence by the Infectious Diseases Society of America (IDSA), recognizing a commitment to reducing infections caused by antimicrobial resistance.
A statewide pay-for-performance intervention based on a set of guidelines called Choosing Wisely reduced rates of inappropriate antibiotic prescriptions to treat acute respiratory tract infections by an average of 18 percentage points, from 43% to 25%, across two large Los Angeles safety net hospitals.
This study is expected to generate critical evidence about the rise and expansion of drug-resistant parasites in Ethiopia. Results will help policymakers and advance malaria elimination efforts in Ethiopia and beyond.
Genes that make bacteria resistant to antibiotics are much more widespread in our environment than was previously realised.
Survival rate beyond 10 years in children with drug-resistant epilepsy (DRE) was highest after cranial epilepsy surgery and lowest when treated only with antiseizure medications, according to a study published in The Lancet Child and Adolescent Health. This large, retrospective study was the first to compare long-term survival in children with DRE among cohorts treated with medications only, vagus nerve stimulation plus medications, and cranial epilepsy surgery plus medications. Results show that risk of early death was reduced by over 80 percent after surgery and by 40 percent after vagus nerve stimulation, compared to medication-only treatment.
In the case of blood poisoning, the bacteria in the blood must be identified as fast as possible so that a life-saving therapy can be started. Empa researchers have now developed "sepsis sensors" with magnetic nanoparticles that detect bacterial pathogens within a short period of time and identify suitable candidates for antibiotic therapies.
Antibiotic resistance (ARE) is a threat to human health worldwide, as diverse proteins allow pathogenic bacteria to develop increasing levels of resistance to antibiotic medicines.
Scientists at McMaster University and the Massachusetts Institute of Technology have used artificial intelligence to discover a new antibiotic which could be used to fight a deadly, drug-resistant pathogen that strikes vulnerable hospital patients.
A new tool which could help reduce the spread of antimicrobial resistance is showing early promise, through exploiting a bacterial immune system as a gene editing tool.
The public are in favour of the development of bacteria-killing viruses as an alternative to antibiotics – and more efforts to educate will make them significantly more likely to use the treatment, a new study shows.
Researchers in UNC’s School of Medicine’s department of Microbiology and Immunology and the UNC-NC State Joint Department of Biomedical Engineering have developed a new strategy to improve drug-delivery into chronic wounds infections.
An international team, led by Macquarie University researchers Dr. Ram Maharjan and Associate Professor Amy Cain, have discovered how the superbug can survive harsh environments and then rebound, causing deadly infections. They have found a single protein that acts as a master regulator.
The spread of drug-resistant microbes has become a global health concern that threatens our ability to treat infections. The widespread use of antimicrobials in livestock, such as swine farms, exacerbates this problem.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
